British Journal of Clinical Pharmacology · 2013 · 364 citations · 30 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyMolecular PharmacologyPharmacodynamicsCytochrome P450 EnzymesCytochrome P450 InteractionsCytochrome P450-mediated MetabolismDrug DispositionDrug-metabolizing EnzymesBreast Cancer Resistance MechanismsBreast Cancer Resistance Protein InteractionsCyp3a4 InteractionsCyp450-mediated InteractionsCytochrome P450 3A4 MetabolismCytochrome P450 Enzyme InhibitionCytochrome P450 Kinetics
Rivaroxaban is an oral direct factor Xa inhibitor whose metabolism and excretion involve CYP3A4, CYP2J2, P‑gp, and BCRP pathways. The study evaluated the pharmacokinetic interactions of rivaroxaban with substrates or inhibitors of CYP3A4, P‑gp, and BCRP in healthy volunteers. Rivaroxaban showed no clinically relevant interaction with the CYP3A4 probe midazolam, modest exposure increases with moderate inhibitors (erythromycin, clarithromycin, fluconazole), and marked exposure increases with strong inhibitors (ketoconazole, ritonavir), indicating it can be co‑administered with CYP3A4/P‑gp substrates or moderate inhibitors but not with strong combined CYP3A4/P‑gp/BCRP inhibitors.
Aims The anticoagulant rivaroxaban is an oral, direct F actor X a inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve cytochrome P450 3A4 ( CYP3A4 ) and 2J2 ( CYP2J2 ), CYP ‐independent mechanisms, and P ‐glycoprotein ( P ‐gp) and breast cancer resistance protein ( B crp) ( ABCG2 ). Methods The pharmacokinetic effects of substrates or inhibitors of CYP3A4 , P ‐gp and B crp ( ABCG2 ) on rivaroxaban were studied in healthy volunteers. Results Rivaroxaban did not interact with midazolam ( CYP3A4 probe substrate). Exposure to rivaroxaban when co‐administered with midazolam was slightly decreased by 11% (95% confidence interval [ CI ] −28%, 7%) compared with rivaroxaban alone. The following drugs moderately affected rivaroxaban exposure, but not to a clinically relevant extent: erythromycin (moderate CYP3A4 / P ‐gp inhibitor; 34% increase [95% CI 23%, 46%]), clarithromycin (strong CYP3A4 /moderate P ‐gp inhibitor; 54% increase [95% CI 44%, 64%]) and fluconazole (moderate CYP3A4 , possible B crp [ ABCG2 ] inhibitor; 42% increase [95% CI 29%, 56%]). A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4 , P ‐gp/ B crp ( ABCG 2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95% CI 134%, 174%]). Conclusions Results suggest that rivaroxaban may be co‐administered with CYP3A4 and/or P ‐gp substrates/moderate inhibitors, but not with strong combined CYP3A4 , P ‐gp and B crp ( ABCG2 ) inhibitors (mainly comprising azole‐antimycotics, apart from fluconazole, and HIV protease inhibitors), which are multi‐pathway inhibitors of rivaroxaban clearance and elimination.
30
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
New England Journal of Medicine · 2010 · 3.2K citations · Full text
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega, Eugene Braunwald, Stephen D. Wiviott et al. · New England Journal of Medicine · 2011 · 1.9K citations · Full text
Medicine, Cardiology, Pharmacology +13